We’re pleased to share that three new manuscripts in JACC Journals and one in #EHJ have been published with additional results from SEQUOIA-HCM, our pivotal Phase 3 clinical trial in #HCM. https://bit.ly/3XzjHD2
Cytokinetics
Biotechnology Research
South San Francisco, California 25,881 followers
Empowering Muscle Empowering Lives
About us
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
- Website
-
http://www.cytokinetics.com
External link for Cytokinetics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 1998
- Specialties
- Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
Locations
-
Primary
350 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Cytokinetics
-
Christopher Brey
Senior Director, Facilities and EHS
-
Brett Pletcher
Chief Legal Officer, Cytokinetics; Life Sciences and Public Company Advisor, Gunderson Dettmer; and Former General Counsel at Gilead Sciences
-
Stefan Engst
Principal Scientist at Cytokinetics
-
Kapil Menghrajani
Biopharmaceutical and Medical Diagnostic Professional
Updates
-
#TeamCyto was proud to return for the ninth year to the ALS Network Napa Valley Ride to Defeat ALS and Walk! Our team of 36 employees, family, and friends rode distances ranging from 28 to 90 miles to raise awareness and make a difference for people living with #ALS, their families, friends and #caregivers! Great job, team!
-
Join us in celebrating Hispanic Heritage Month. This year’s theme — Pioneers of Change: Shaping the Future Together — is meant to capture the spirit of innovation, resilience, and unity that define the Hispanic experience. Read what our own employees have to say about their experiences. #HispanicHeritageMonth
-
We're looking forward to attending and presenting at the 2024 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions and the Heart Failure Society of America Annual Scientific Meeting, both in Atlanta later this month. https://bit.ly/4e11gwx #HCM #HFSA2024
-
For the third year in a row, we've been recognized as one of Great Place To Work US & Fortune Magazine's #BestWorkplaces in #Biopharma! Thank you to our dedicated team of innovators, collaborators, and solution-seekers for making Cytokinetics the extraordinary place it is. https://bit.ly/3zhGbPr
-
Over the weekend, we presented data from the Phase 1 study of CK-586 in a poster session at the the American College of Clinical Pharmacology® #2024ACCP Annual Meeting. Read more: https://bit.ly/4efUkLY
-
HeartBrothers Foundation is a recipient of our 2024 Communications Grant. The HeartBrothers will use this grant to expand outreach efforts, foster digital and in-person partnerships with heart failure hospitals nationwide, and increase overall awareness and information about patient resources. https://bit.ly/4gak0LF #heartfailureawareness
-
We're excited to highlight one of our 2024 Communications Grant recipients: WomenHeart: The National Coalition for Women with Heart Disease. Founded in 1999 by three women, WomenHeart will use this funding to raise awareness of women’s heart health by spotlighting powerful stories that inspire and empower women to take control of their heart health. https://bit.ly/3AL1t8m #hearthealth
-
Tomorrow we’re hosting an investor conference call to discuss the new data presented from SEQUOIA-HCM and FOREST-HCM. Join us at 8:00 AM ET: https://bit.ly/4g6qknr
-
Today we presented new data related to our investigational cardiac myosin inhibitor from SEQUOIA-HCM and FOREST-HCM in #HCM. Learn more here: https://bit.ly/4dLKp0z